Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient's perspective

Virginia Pascual-Ramos, Irazú Contreras-Yáñez, Virginia Pascual-Ramos, Irazú Contreras-Yáñez

Abstract

Background: Knowledge of factors that contribute to non-persistence with disease modifying anti-rheumatic drugs (NP) is essential to improve rheumatoid arthritis (RA) outcomes. Aims of the study were to investigate patient's motivations and risk factors for NP in a cohort of early RA patients.

Methods: Up to September 2012, data from 149 patients, who had at least 1 year of follow-up, at least one drug indication, and at least 2 consecutive six-months-apart rheumatic evaluations that included assessment of compliance were reviewed. NP and patient's motivations of NP were evaluated according to a questionnaire. NP was defined when patients referred that they had completely stop RA medication, "Sometimes", "Almost always" or "Always". Patients had to pay for their medication.Descriptive statistics and logistic regression models were used. Statistical significance was set at a p value of less than 0.05. The study was approved by the internal review board.

Results: Up to cut-off, 715 questionnaires were applied to 149 patients, who had follow-up of 58.7 ± 27.9 months and were indicated 2.4 ± 0.7 DMARDs/patient/follow-up.Patients were most frequently female (88.6%), middle-aged ([mean ± SD] age of 38.5 ± 12.8 years) with lower-middle/lower socio-economic status (87.9%) and scholarship of 11 ± 3.9 years.Ninety-nine (66.4%) patients were NP and filled 330 questionnaires. Multivariate analysis showed that years of formal education (OR: 1.12, 95% CI: 1.1-1.24, p = 0.03), perception of at least some difficulty to find arthritis medication (OR: 5.68, 95% CI: 2.48-13, p = 0.000) and perception that arthritis medication is expensive (OR: 5.27, 95% CI: 2.1-13.84, p = 0.001) at the first evaluation of patient's compliance were all predictors of NP.Among the 99 NP patients, 25 (25.3%) were recurrent-NP and accumulated more disease activity. The combination of both reasons of NP ("Because it was not available at the drugstore" and "Because the medication is very expensive") when selected at the first evaluation of compliance was the only variable to predict recurrent NP, OR: 4.8, 95% CI: 1.1-20.8, p = 0.04.

Conclusions: Health systems should provide (first line) treatment for RA as a strategy to improve compliance with therapy and clinical outcomes, particularly in vulnerable populations.

References

    1. Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, Perfetto EM. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care. 2002;8:231–40.
    1. Sanderson T, Kirwan J. Patient-reported outcomes for arthritis: time to focus on personal life impact measures? Arthritis Rheum. 2009;61:1–3.
    1. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–494. doi: 10.1002/art.1780370408.
    1. Mody GM, Cardiel MH. Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol. 2008;22:621–641. doi: 10.1016/j.berh.2008.04.003.
    1. Pascual-Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J, Rull-Gabayet M. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther. 2009;11:R26. doi: 10.1186/ar2620. doi:10.1186/ar2620.
    1. de Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient Compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30:44–54.
    1. Gossec L, Tubach F, Dougados M, Ravaud P. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci. 2007;334:248–254. doi: 10.1097/MAJ.0b013e318068dde8.
    1. Deyo RA, Inui TS, Sullivan B. Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications. J Rheumatol. 1981;8:931–936.
    1. Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int. 2007;27:743–746. doi: 10.1007/s00296-006-0299-9.
    1. García-González A, Richardson M, García Popa-Lisseanu M, Cox V, Kallen MA, Janssen N, Ng B, Marcus DM, Reveille JD, Suárez-Almazor ME. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008;27:883–889. doi: 10.1007/s10067-007-0816-6.
    1. Lorish CD, Richards B, Brown S. Missed medication doses in rheumatic arthritis patients: intentional and unintentional reasons. Arthritis Care Res. 1989;2:3–9. doi: 10.1002/anr.1790020103.
    1. Lorish CD, Richards B, Brown S Jr. Perspective of the patient with rheumatoid arthritis on issues related to missed medication. Arthritis Care Res. 1990;3:78–84.
    1. Viller F, Guillemin F, Briançon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol. 1999;26:2114–2122.
    1. Viller F, Guillemin F, Briançon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance with drug therapy in rheumatoid arthritis. A longitudinal European study. Joint Bone Spine. 2000;67:178–182.
    1. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR. Assessment of adherence to and persistence on disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45(Suppl 2):S66–76. doi: 10.1097/MLR.0b013e318041384c.
    1. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patients out-of-pocket payments matter? Arthritis Rheum. 2008;59:1519–1526. doi: 10.1002/art.24114.
    1. Contreras Yanez I, Ponce De Leon S, Cabiedes J, Rull Gabayet M, Pascual Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease modifying anti-rheumatic drugs. Am J Med Sci. 2010;340:282–290. doi: 10.1097/MAJ.0b013e3181e8bcb0.
    1. Contreras-Yáñez I, Cabiedes J, Villa AR, Rull-Gabayet M, Pascual-Ramos V. Persistence on therapy is a major determinant of patient-, physician-, and laboratory reported outcomes in recent-onset rheumatoid arthritis patients. Clin Exp Rheumatol. 2010;28:748–51.
    1. Lim TO, Ngah BA. The Mentakab hypertension study project. Part II- why do hypertensives drop out of treatment? Singapore Med J. 1991;32:249–251.
    1. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag. 2008;4:269–286.
    1. Prevoo ML, Van T, Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–48. doi: 10.1002/art.1780380107.
    1. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52:2625–2636. doi: 10.1002/art.21235.
    1. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992; status and review. Arthritis Care Res. 1992;5:119–129. doi: 10.1002/art.1790050303.
    1. Lee P, Tan LJ. Drug compliance in outpatients with rheumatoid arthritis. Aust N Z J Med. 1979;9:274–277. doi: 10.1111/j.1445-5994.1979.tb04138.x.
    1. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appaisal of the existing literature. Expert Rev Clin Immunol. 2012;8:337–351. doi: 10.1586/eci.12.23.
    1. World Health Organization. Adherence to long-term therapies: evidence for action. 2003. [ ]
    1. Hernández-Ronquillo L, Téllez-Zenteno JF, Garduño-Espinosa J, González-Acevez E. Factors associated with therapy non-compliance in type 2-diabetes patients. Salud Publica Mex. 2003;45:191–197. doi: 10.1590/S0036-36342003000300008.
    1. Ponnusankar S, Surulivelrajan M, Anandamoorthy N, Suresh B. Assessment of impact of medication counseling in patient’s medication knowledge and compliance in an outpatient clinic in South India. Patient Educ Couns. 2004;54:55–60. doi: 10.1016/S0738-3991(03)00193-9.
    1. Okuno J, Yanagi H, Tomura S, Oka M, Hara S, Hirano C, Tsuchiya S. Compliance and medication knowledge among elderly Japanese home-care recipients. Eur J Clin Pharmacol. 1999;55:145–149. doi: 10.1007/s002280050609.
    1. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19:638–645. doi: 10.1111/j.1525-1497.2004.30516.x.
    1. Kaplan RC, Bhalodkar NC, Brown EJ Jr, White J, Brown DL. Race, ethnicity and sociocultural characteristics predict noncompliance with lipid-lowering medications. Prev Med. 2004;39:1249–1255. doi: 10.1016/j.ypmed.2004.04.041.
    1. Swett C Jr, Noones J. Factors associated with premature termination from outpatient treatment. Hosp Community Psychiatry. 1989;40:947–951.
    1. Mishra P, Hansen EH, Sabroe S, Kafle KK. Socio-economic status and adherence to tuberculosis treatment: a case control study in a district of Nepal. Int J Tuberc Lung Dis. 2005;9:1134–1139.
    1. Ghods AJ, Nasrollahzadeh D. Noncompliance with immunosuppressive medications after renal transplantation. Exp Clin Transplant. 2003;1:39–47.
    1. Kyngas H, Lahdenpera T. Compliance of patients with hypertention and associated factors. J Ad Nur. 2000;29:832–839.
    1. Senior V, Marteau TM, Weinman J. Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions. Cardiovas Drug Ther. 2004;18:475–481. doi: 10.1007/s10557-004-6225-z.
    1. DiMatteo MR. Patients adherence to pharmacotherapy: the importance of effective communication. Formulary. 1995;30:596–598. 601–2, 605.
    1. Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers and intentional nonadherers: application of the necessity-concerns framework. J Psychosom Res. 2008;64:41–46. doi: 10.1016/j.jpsychores.2007.05.004.
    1. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatol (oxford) 2005;44:762–7. doi: 10.1093/rheumatology/keh587.
    1. van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 2007;7:55. doi: 10.1186/1472-6963-7-55.
    1. Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis. 2001;60:869–875.
    1. Brus HLM, van de Laar MAFJ, Taal E, Rasker JJ, Wiegman O. Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. Ann Rheum Dis. 1998;57:146–151. doi: 10.1136/ard.57.3.146.
    1. van den Bemt BJ, den Broeder AA, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W. Making the rheumatologist aware of patients’ non-adherence does not improve medication adherence in patients with rheumatoid arthritis. Scan J Rheumatol. 2011;40:192–196. doi: 10.3109/03009742.2010.517214.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj